TME Pharma
 | This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (December 2018) |
 | |
| Company type | Aktiengesellschaft |
|---|---|
| Founded | 1997 |
| Headquarters | Berlin, Germany |
Key people |
|
Number of employees | 10 (2017)[1] |
| Website | www.tmepharma.com |
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris (ALTME)and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller (vfa).
TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers,[2][3] from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes.[4]
Products
[edit]Some Spiegelmer candidates were in clinical trials.
A Spiegelmer (NOX-A12, olaptesed pegol) was under development as a combination therapy for a number of cancer indications. NOX-A12 targets CXCL12 (C-X-C Chemokine Ligand 12), a key chemokine protein. Favorable results were reported in October 2018 during the 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York, NY, USA.[5][6][7][8]
A different Spiegelmer (NOX-E36, emapticap pegol) was tested for the treatment of progressive diabetic nephropathy.[9] Favorable results were reported in June 2014 in a company press release.[10] NOX-E36 targets MCP-1, also called CCL2.[4]
A third Spiegelmer (NOX-H94, lexaptepid pegol) was in a clinical trial for the treatment of anemia of chronic disease.[11][12]
References
[edit]- ^ Investors. Noxxon.com. Retrieved on 2018-02-14.
- ^ Vater A, Klussmann S (March 2003). "Toward third-generation aptamers: Spiegelmers and their therapeutic prospects". Curr Opin Drug Discov Dev. 6 (2): 253–61. PMID 12669461.
- ^ Eulberg D; et al. (2006), "Spiegelmers for Therapeutic Applications", The Aptamer Handbook (in German), WILEY-VCH, pp. 417–42, ISBN 3-527-31059-2
- ^ a b "News Review: Aram Mangasarian, Noxxon Pharma AG". pharmatelevision.com. Archived from the original on 2013-05-24. Retrieved 2013-07-16.
- ^ Clinical trial number NCT03168139 for "Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer" at ClinicalTrials.gov
- ^ Clinical trial number NCT01521533 for "NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma" at ClinicalTrials.gov
- ^ Clinical trial number NCT01486797 for "NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia" at ClinicalTrials.gov
- ^ "Noxxon Presents Top-Line Data from Nox-A12 Monotherapy Part of Ongoing Metastatic Colorectal and Pancreatic Cancer Trial" (PDF) (Press release). Noxxon. October 2, 2018.
- ^ Clinical trial number NCT01547897 for "NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria" at ClinicalTrials.gov
- ^ "Noxxon's Emapticap Pegol Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA Conference" (PDF) (Press release). Noxxon. June 2, 2014.
- ^ Clinical trial number NCT01691040 for "Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer" at ClinicalTrials.gov
- ^ Schwoebel F, et al. (March 2013). "The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys". Blood. 121 (12): 2311–5. doi:10.1182/blood-2012-09-456756. PMC 3606066. PMID 23349391.